Clinical Trial Update: Safety Study of Tenapanor for the Treatment of Pediatric Patients (6 to Less Than 18 Years Old) With IBS-C [Phase 3]

View source ↗

Summary

This clinical trial update outlines a Phase 3 safety study of tenapanor in pediatric patients aged 6 to under 18 with irritable bowel syndrome with constipation…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Irritable Bowel Syndrome with Constipation

Drugs mentioned

• Tenapanor (tenapanor)

Snippet

Sponsor: Ardelyx | Conditions: Irritable Bowel Syndrome With Constipation (IBS-C) | Phase 3 | Status: ENROLLING_BY_INVITATION